![Konstantinos Xynos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 3 M $ in data 31/07/2026
Konstantinos Xynos is Chief Medical Officer at Replimune Group, Inc. since 2022.
Formerly, Dr. Xynos was Vice President & Head-Global Medical Affairs at Deciphera Pharmaceuticals, Inc. from 2019 to 2021.
Education includes an undergraduate degree from the University of Illinois (1991), a doctorate from Aristotle University of Thessaloniki (1997), a doctorate from National & Kapodistrian University of Athens (2012), and an MBA from the University of Strathclyde (2013).
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 10/08/2026 | 224.215 ( 0,29% ) | 3 M $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| REPLIMUNE GROUP, INC. | Direttore Tecnico/Scientifico/R&S | 01/12/2022 |
| Società | Posizione | Fine |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2021 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 6 |
|---|---|
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
 University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aristotle University of Thessaloniki
 Aristotle University of Thessaloniki Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National & Kapodistrian University of Athens
 National & Kapodistrian University of Athens Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
